References
- 1. O’Brien MN, Jiang W, Wang Y, Loffredo DM. Challenges and opportunities in the development of complex generic long-acting injectable drug products. J Control Release. 2021; 336:144-158.10.1016/j.jconrel.2021.06.01734126170
- 2. Chazin H, Woo J, Han J, Grosser S, Luan J. FDA’s Generic Drug Program: Decreasing Time to Approval and Number of Review Cycles. Ther Innov Regul Sci. 2020;54(4):758-763.10.1007/s43441-019-00016-232557293
- 3. Woo J, Luan JJ, Li Z, Grosser S, Peters J, Chazin H. Abbreviated New Drug Applications: Generic Drug User Fee Amendments Act Analysis of Application Quality Metrics. Ther Innov Regul Sci. 2019;53(5):696-700.10.1177/216847901880619230360656
- 4. Food and Drug Administration. Silver spring: The competitive Generic Therapy; [updated 2021 Aug 06; cited 2021 Aug 12]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies
- 5. Food and Drug Administration. Silver spring: Patent Challenge exclusivity; [updated 2021 Aug 02; cited 2021 Aug 10]. Available from: https://www.fda.gov/drugs/cder-small-business-industry-assistance-sbia/small-business-assistance-180-day-generic-drug-exclusivity
- 6. Gurgula O. Strategic Patenting by Pharmaceutical Companies–Should Competition Law Intervene?. IIC-International Review of Intellectual Property and Competition Law. 2020;51(9):1062-85.10.1007/s40319-020-00985-0759214033132411
- 7. Sahragardjoonegani B, Beall RF, Kesselheim AS, Hollis A. Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997. Journal of pharmaceutical policy and practice. 2021;14(1):1-8.10.1186/s40545-020-00282-8778060733397471
- 8. Holman CM, Minssen T, Solovy EM. Patentability standards for follow-on pharmaceutical innovation. Biotechnology Law Report. 2018;37(3):131-61.10.1089/blr.2018.29073.cmh
- 9. Hering S, Loretz B, Friedli T, Lehr CM, Stieneker F. Can lifecycle management safeguard innovation in the pharmaceutical industry? Drug Discov Today. 2018;23(12):1962-1973.10.1016/j.drudis.2018.10.00830342247
- 10. Xie J. Horizontal Shareholdings and Paragraph IV Generic Entry in the U.S. Pharmaceutical Industry. The Antitrust Bulletin. 2021;66(1):100-112.10.1177/0003603X20985797
- 11. Beall RF, Ronksley PE, Wick J, Darrow JJ, Sarpatwari A, Kesselheim AS. Comparing Onset of Biosimilar Versus Generic Competition in the United States. Clin Pharmacol Ther. 2020;108(6):1308-1314.10.1002/cpt.198132621540
- 12. Gupta R, Shah ND, Ross JS. Generic drugs in the United States: policies to address pricing and competition. Clinical Pharmacology & Therapeutics. 2019;105(2):329-37.10.1002/cpt.1314635535630471089
- 13. Olson LM, Wendling BW. Estimating the causal effect of entry on generic drug prices using Hatch–Waxman exclusivity. Review of Industrial Organization. 2018; 53(1):139-72.10.1007/s11151-018-9627-y
- 14. Bernstein JJJ, Holt GB, Bernstein J. Price dispersion of generic medications. PLoS One. 2019; 14(11): e0225280.10.1371/journal.pone.0225280686093231738807
- 15. Food and Drug Administration. Silver spring: Total Generic’s approved;[updated 2021 Sep 23; cited 2021 Aug 05]. Available from: https://www.accessdata.fda.gov/scripts/cder/daf/
- 16. Food and Drug Administration. Silver spring: First generic drugs;[updated 2021 Sep 28; cited 2021 Aug 07]. Available from: https://www.fda.gov/drugs/drug-and-biologic-approval-and-ind-activity-reports/first-generic-drug-approvals
- 17. Food and Drug Administration. Silver spring: Patent Challenge exclusivity; [updated 2021 Aug 02; cited 2021 Aug 10]. Available from: https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/patent-certifications-and-suitability-petitions
- 18. Food and Drug Administration. Silver spring: The competitive Generic Therapy; [updated 2021 Aug 06; cited 2021 Aug 12]. Available from: https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals
- 19. United States District Court for the District of Delaware. Generic drugs Patent litigations; [updated 2021 Sep 25; cited 2021 Aug 02]. Available from: https://www.ded.uscourts.gov/
- 20. Food and Drug Administration. Silver spring: orange book; [updated 2021 Aug 06; cited 2021 Aug 09]. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
- 21. Beall RF, Darrow JJ, Kesselheim AS. A method for approximating future entry of generic drugs. Value in Health. 2018;21(12):1382-9.10.1016/j.jval.2018.04.182730502781
- 22. Lee Y, Fong EA. Patent lifecycle management strategies in open innovation projects. Drug Discovery Today. 2020;25(10):1782-5.10.1016/j.drudis.2020.06.01932592662
- 23. Darrow JJ, Beall RF, Kesselheim AS. The Generic Drug Industry Embraces a Faster, Cheaper Pathway for Challenging Patents. Appl Health Econ Health Policy. 2019; 17(1):47-54.10.1007/s40258-018-0420-830141133
- 24. Agranat I, Marom H. In Defense of Secondary Pharmaceutical Patents in Drug Discovery and Development. ACS Med Chem Lett. 2020; 11(2):91-98.10.1021/acsmedchemlett.9b00497710698532280427
- 25. Socal MP, Parasrampuria S, Anderson GF. Modifying the Criteria for Granting Orphan Drug Market Exclusivity. Value Health. 2020; 23(11):1470-1476.10.1016/j.jval.2020.08.00433127018
- 26. Kerr KW, Glos LJ. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases. Pharmaceut Med. 2020; 34(1):19-29.10.1007/s40290-019-00317-9
- 27. Beall RF, Kesselheim AS, Sarpatwari A. New Drug Formulations and Their Respective Generic Entry Dates. J Manag Care Spec Pharm. 2019;25(2):218-224.10.18553/jmcp.2019.25.2.21830698097
- 28. Fermont I. Pharmacovigilance strategy: opportunities for cross-national learning. Isr J Health Policy Res. 2019; 8(1):54.10.1186/s13584-019-0319-3658255731217025
- 29. Bejarano A, Hewa Nadungodage C, Wang F, Catlin AC, Hoag SW. Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing. AAPS PharmSciTech. 2019; 20(6):223.10.1208/s12249-019-1440-x31214878
- 30. Leistner A, Haerling S, Kreher JD, Becker I, Jung D, Holzgrabe U. Risk assessment report of potential impurities in cetirizine dihydrochloride. J Pharm Biomed Anal. 2020; 189:113425.10.1016/j.jpba.2020.11342532599488
- 31. Ermer J, Aguiar D, Boden A, Ding B, Obeng D, Rose M, Vokrot J. Lifecycle management in pharmaceutical analysis: How to establish an efficient and relevant continued performance monitoring program. J Pharm Biomed Anal. 2020; 181:113051.10.1016/j.jpba.2019.11305131962246
- 32. Charoo NA. Converging Generic Drug Product Development: Bioequivalence Design and Reference Product Selection. Clin Pharmacokinet. 2020; 59(11):1335-1355.10.1007/s40262-020-00912-z32757104
- 33. Zhao L, Kim MJ, Zhang L, Lionberger R. Generating Model Integrated Evidence for Generic Drug Development and Assessment. Clin Pharmacol Ther. 2019; 105(2):338-349.10.1002/cpt.128230414386
- 34. Rattan AK. Data Integrity: History, Issues, and Remediation of Issues. PDA J Pharm Sci Technol. 2018; 72(2):105-116.10.5731/pdajpst.2017.00776529158286
- 35. Fermaglich LJ, Chen R, Kim CY, Chuh EE, Thomas T, Shetty D, Lee J, Young J, Fan Y. Common Filing Deficiencies in Abbreviated New Drug Applications Containing Clinical Endpoint Studies. Ther Innov Regul Sci. 2019; 53(1):81-85.10.1177/216847901876929829719976
- 36. Kugener VF, Freedland ES, Maynard KI, Aimer O, Webster PS, Salas M, Gossell-Williams M. Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Safety. 2021;1-0.10.1007/s40264-021-01078-8812309933993430
- 37. Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020; 19(11):1505-1511.10.1080/14740338.2020.179997532693646
- 38. Wittayanukorn S, Rosenberg M, Schick A, Hu M, Wang Z, Babiskin A, Lionberger R, Zhao L. Factors that have an Impact on Abbreviated New Drug Application (ANDA) Submissions. Ther Innov Regul Sci. 2020; 54(6):1372-1381.10.1007/s43441-020-00163-x32495310